Capital Advisors Ltd. adds Celgene Corporation (CELG) to its portfolio

Celgene Corporation (CELG) : Capital Advisors Ltd. added new position in Celgene Corporation during the most recent quarter end. The investment management firm now holds 200 shares of Celgene Corporation which is valued at $19,700 , the company said in a statement filed on Oct 14, 2016 with the SEC.Celgene Corporation makes up approximately 0.01% of Capital Advisors Ltd.’s portfolio.

Other Hedge Funds, Including , Pennsylvania Trust Co boosted its stake in CELG in the latest quarter, The investment management firm added 9,991 additional shares and now holds a total of 49,611 shares of Celgene Corporation which is valued at $4,886,684. Celgene Corporation makes up approx 0.40% of Pennsylvania Trust Co’s portfolio. Fox Run Management L.l.c. sold out all of its stake in CELG during the most recent quarter. The investment firm sold 4,300 shares of CELG which is valued $437,052. Centre Asset Management sold out all of its stake in CELG during the most recent quarter. The investment firm sold 49,990 shares of CELG which is valued $5,212,457.Burns J W Co Incny boosted its stake in CELG in the latest quarter, The investment management firm added 1,070 additional shares and now holds a total of 29,115 shares of Celgene Corporation which is valued at $3,065,518. Celgene Corporation makes up approx 0.95% of Burns J W Co Incny’s portfolio.New England Research Management reduced its stake in CELG by selling 3,000 shares or 16.9% in the most recent quarter. The Hedge Fund company now holds 14,755 shares of CELG which is valued at $1,553,554. Celgene Corporation makes up approx 1.31% of New England Research Management’s portfolio.

Celgene Corporation closed down -2.13 points or -2.12% at $98.5 with 43,17,515 shares getting traded on Friday. Post opening the session at $101.25, the shares hit an intraday low of $98.48 and an intraday high of $101.389 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.